



Direct Healthcare Professional Communication

Sep 2023

Terbutaline Turbuhaler and Terbutaline nebulizer: important information to convey to patients

Dear Healthcare Professional,

The General Administration for Pharmaceutical Vigilance of the Central Administration for Pharmaceutical Care at The Egyptian Drug Authority would like to inform you of the following important information to your patients :

When dispensing terbutaline, you must provide the following information to your patients:

- **Terbutaline** should be used as needed rather than regularly.
- Patients should contact their doctor promptly:
- If asthma symptoms get worse (cough, shortness of breath, wheezing, or chest tightness) or if they feel short of breath when talking, eating, or sleeping.
- If they need higher doses of **Terbutaline** than usual to relieve their breathing problems. They may then need additional medications to control their asthma.
- If **Terbutaline** is used more than twice a week to treat asthma symptoms. This indicates poorly controlled asthma and an increased risk of severe asthma attacks (worsening of asthma) and serious complications that can be life-threatening and lead to death. The doctor can then reassess the asthma treatment.
- If patients use a medication for lung inflammation, such as an inhaled corticosteroid, on a daily basis, it is important to continue using it regularly, even if they feel better.
- We ask that you please inform patients of these changes.

References:

ANSM: <https://ansm.sante.fr/uploads/2023/07/06/20230706-dhpc-bricanyl.pdf>

Call for reporting

Healthcare professionals are asked to report any suspected adverse reactions via the Egyptian reporting system:

Name: General Administration for Pharmaceutical Vigilance

Email: pv.followup@edaegypt.gov.eg

Online reporting: <https://primaryreporting.who-umc.org/EG>

QR Code:

Hotline: 15301

